Related Experiment Videos
Immunomodulation by treatment with Lactobacillus casei strain Shirota
1Yakult Central Institute for Microbiological Research, Tokyo, Japan.
International Journal of Food Microbiology
|August 15, 1998
Summary
Lactobacillus casei strain Shirota (LcS) demonstrates significant anti-tumour effects, inhibiting tumor growth and metastasis. Oral and intrapleural administration of LcS modulates immune responses, suggesting potential for disease prevention and treatment.
Area of Science:
- Immunology
- Microbiology
- Oncology
Background:
- Lactobacillus casei strain Shirota (LcS) exhibits anti-tumour and anti-metastatic properties.
- Previous studies indicate LcS can suppress chemically-induced carcinogenesis in rodents.
Purpose of the Study:
- To investigate the anti-tumour effects of Lactobacillus casei strain Shirota (LcS).
- To explore the immunomodulatory mechanisms of LcS in cancer-bearing models.
Main Methods:
- Intrapleural (i.pl.) and oral administration of LcS in rodent models.
- Assessment of tumour growth, survival rates, and cytokine production (IFN-gamma, IL-1beta, TNF-alpha).
- Evaluation of mitogenic responses in tumour-bearing mice.
Main Results:
- Intrapleural LcS administration inhibited thoracic cavity tumor growth and prolonged survival.
- LcS administration induced key cytokines, correlating with tumor inhibition and increased survival.
- Oral LcS administration suppressed tumor growth, restored immune response, and inhibited bladder cancer.
Conclusions:
- LcS demonstrates potent anti-tumour and anti-metastatic effects via immune system modulation.
- LcS treatment holds potential for preventing and ameliorating various diseases by enhancing cellular immunity.